Clinical Trial Update: Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) [Phase 1, Phase 2]

View source ↗

Summary

This is a clinical trial update for patritumab deruxtecan (MK-1022-011) in gastrointestinal cancers. The study is in Phase 1/Phase 2 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastrointestinal Cancer | Phase 1, Phase 2 | Status: RECRUITING